Achalasia: diagnosis, treatments, nutrition and safety

Direct answer: Achalasia causes impaired movement of the food pipe and failure of its lower muscle valve to relax. It needs specialist diagnostic testing and treatment directed at that obstruction to emptying. Pneumatic dilation, Heller myotomy and peroral endoscopic myotomy (POEM) are established options; none restores normal lost nerves. Confidence: high for the need to investigate swallowing difficulty; moderate for this broad care summary, which uses clinical guidance rather than an independently re-audited head-to-head treatment comparison. No supplement cure is established in the sources reviewed.

Key takeaways
  • Difficulty swallowing liquids as well as solids, undigested-food regurgitation and weight loss warrant assessment.
  • Pressure testing, imaging and endoscopy answer different diagnostic questions.
  • The manometry subtype, previous procedures and fitness for treatment affect the specialist discussion.
  • Food adaptations can support intake but cannot establish that oesophageal emptying is safe.
  • New severe symptoms after dilation or myotomy need urgent assessment.

Table of contents

Evidence summary

Clinical guidance, human outcome research and funding independence answer different questions. The guidance below explains care; it does not independently reproduce the trials behind a medicine or supplement.

Claim / interventionEvidence reviewedFunding / conflictsInterpretation / limits
Pressure testing, imaging and endoscopyNational NHS and original ACG clinical guidancePublic education; ACG declares device-industry interestsComplementary diagnostic roles; not a self-diagnosis.
Dilation, Heller myotomy and POEMNational NHS and hospital procedure informationPublic/mixed provider income; source trials not clearedEstablished clinical options; no independently cleared head-to-head ranking here.
Food and nutrition adaptationsDorset leaflet and dysphagia guidancePublic-provider finances/page gaps; older materialsSupport intake and safety; do not establish correction of motility.
Supplements as a cureNo eligible disease-cure evidence established in this reviewNutrient safety pages are not efficacy trialsDo not replace assessment or treatment.

What achalasia is

Achalasia affects the oesophagus, the muscular tube carrying food from the mouth to the stomach. Swallowed material may remain above its lower sphincter instead of passing normally. People can experience chest discomfort, undigested food coming back up, cough or progressively difficult eating. Symptoms sometimes resemble reflux, which can delay recognition. These features are described in NHS patient guidance.

“Dysphagia” means difficulty swallowing; it is a symptom, not a diagnosis of achalasia. A narrowed food pipe, cancer, neurological swallowing problems and other disorders can cause it. Keep this distinction in mind when searching for treatment: an article about relaxing the lower sphincter cannot tell you which of these problems you have.

How it works

The coordination of oesophageal muscle movement and sphincter relaxation is disrupted. Retained food can stretch the oesophagus and irritate its lining; material that comes back up can enter the airway. The Dorset leaflet explains these mechanisms. The underlying cause is incompletely understood; a plausible nerve or immune mechanism does not identify a supplement that reverses it.

High-resolution manometry classifies types I, II and III by pressure and contraction patterns. These are clinical test findings, rather than three diagnoses that can be selected from symptoms alone. The original ACG guideline uses this classification to inform care. Endoscopy also helps exclude an obstructing mass that can mimic achalasia; a treatment decision should follow an adequate diagnostic work-up.

The evidence-based treatments

Pneumatic dilation stretches and disrupts the tight lower sphincter using a balloon. It may require repeated treatment. Heller myotomy cuts muscle surgically, commonly with a partial fundoplication to reduce reflux. POEM cuts muscle through an endoscope from inside the food pipe. Guy’s and St Thomas’ describes these options. They aim to improve passage into the stomach; easier swallowing does not mean the condition has disappeared.

Botulinum toxin injections may offer temporary relief when more definitive treatment is unsuitable. Medicines such as nitrates or nifedipine can relax muscle for a limited period, but do not help everyone. NHS guidance describes these as options to discuss with the treating team. The appropriate choice depends on the complete clinical picture, not whether a procedure is newest or a hospital advertises it prominently.

Useful consultation questions are: What does my pressure test show? Why does this option fit that pattern? What experience does this centre have? What happens if symptoms recur? How will reflux and nutrition be monitored? Ask the team to connect its recommendation to your results and preferences. This review does not provide an independently funded league table of procedures.

Supplement and lifestyle evidence

Nutrition support should begin before weight loss becomes severe. A dietitian can help preserve energy, protein and hydration while the underlying disorder is treated. Softer textures, thorough chewing and upright eating may be useful, as the Dorset patient leaflet discusses. Advice to drink alongside meals is not a universal instruction for someone whose liquids trigger choking; the swallowing assessment takes priority.

Swallowing therapy and fluid-thickness changes serve particular problems. The NHS dysphagia page describes speech-and-language therapy, dietetic support and feeding support when needed. Do not assume that a generic thickener, exercise or smoothie plan addresses the oesophageal emptying problem. Ask which part of swallowing is impaired and what each proposed adaptation is intended to achieve.

We found no financially cleared human evidence in the sources reviewed establishing that probiotics, digestive enzymes, magnesium, herbs or vitamins restore oesophageal nerves or cure achalasia. A nutritional product may help meet an assessed intake need; that is a different endpoint from restoring motility. ODS explains that supplements do not replace a varied diet and quality seals do not guarantee disease efficacy.

What works and what does not

Judge treatment by meaningful follow-up: ability to eat and drink, weight and hydration, regurgitation, complications and the team’s assessment of emptying. A brief reduction in chest discomfort is not enough to demonstrate adequate passage of food. Repeatedly compensating with restricted food choices can hide how much swallowing has deteriorated.

When symptoms continue or return after a procedure, the cause needs reassessment rather than an automatic repeat of the same treatment. It might involve residual emptying problems, reflux or narrowing. The ACG guideline describes structured evaluation of recurrent symptoms. Its underlying studies were not all independently screened here, so this is clinical context rather than a cleared comparative outcome claim.

Risks and side effects

Get prompt medical assessment for difficulty swallowing, choking with meals, food feeling stuck, a wet voice after swallowing or repeated chest infections. These are NHS warning signs. An inability to swallow saliva, severe breathing difficulty or choking that blocks breathing needs emergency care. New severe chest pain should be assessed urgently rather than attributed to an existing digestive diagnosis.

After POEM, fever or worsening chest pain requires urgent contact with the clinical team or emergency assessment. Guy’s and St Thomas’ recovery guidance specifically flags these symptoms. Follow the emergency instructions from your own hospital after dilation or surgery. Do not use expected postoperative discomfort as a reason to ignore a changing or severe symptom.

POEM can cause bleeding, perforation, chest infection, persistent swallowing difficulty and reflux. The hospital’s overview explains these risks. Consent should include how complications would be recognized and managed, and what follow-up is planned. A complication percentage from one institution is not a personalized prediction.

Important interactions

Before a procedure, provide a complete list of prescriptions, non-prescription drugs, supplements and previous anaesthetic problems. Ask explicitly about blood thinners, diabetes medicines and medicines that cannot be safely stopped. The team must supply a written plan; an article cannot balance your clotting and bleeding risks.

If a nitrate is considered, the exact prescription requires a medicine-interaction check. The NHS GTN interaction page warns about excessive blood-pressure reduction and medicines including sildenafil or tadalafil. This is a safety example, not an instruction to use GTN for achalasia. Do not add another muscle-relaxing medicine or an “enhancement” product without disclosing it.

Supplements can affect bleeding, prescribed medicines and anaesthesia. NCCIH and ODS advise discussing them with clinicians before surgery. “Natural” does not establish safety. Bring the actual labels so the team can identify ingredients and formulation, rather than describing a product only as a digestive aid.

Who needs special assessment

Children need a paediatric specialist rather than a scaled-down adult protocol. Great Ormond Street’s older childhood information describes specialist testing and follow-up, but its 2015 review date prevents using it as a current procedure-selection guide. Feeding difficulty, poor growth and respiratory symptoms deserve clinical attention.

People with substantial weight loss, dehydration, recurrent respiratory infections or limited ability to tolerate anaesthesia need coordinated nutrition and treatment planning. Ask how urgency and fitness are being assessed. Pregnancy, frailty and serious coexisting illnesses likewise require individualized discussion; these situations should not be managed through a supplement-first trial while investigations are postponed.

Clinician-led treatment and use

Preparation and recovery instructions vary by hospital and procedure. The Guy’s and St Thomas’ protocol includes pre-assessment, an oesophageal-emptying preparation and a staged return to eating. Its exact fasting and diet timetable should not be copied for another centre. Obtain instructions covering fluids, food texture, medication changes, transport, emergency contacts and follow-up.

For a medicine, agree the intended purpose, duration and review point with the prescriber. For nutrition support, agree how intake, weight and tolerance will be followed. Ask what should trigger earlier contact. Do not crush a tablet, open a capsule or stop a prescription simply because swallowing is difficult; ask a pharmacist for a suitable formulation.

Animal and in-vitro evidence

Nerve, immune and muscle experiments can help explain possible mechanisms, but a laboratory effect cannot show that a human product safely restores swallowing. Animal or cell findings were not counted as clinical efficacy in this guide. A supplement claim would need controlled human outcomes, relevant adverse-event reporting and an audit of sponsors and investigator interests before contributing to an independent verdict.

Funding and source roles

Follow the money

Who paid for the evidence?

Follow named sources to the funding and relationships disclosed in this article. Numbered article disclosures preserve notes where a source is not identified. A public or university name alone does not establish independence.

Public / academicCommercial support or tiesUnknown / not disclosed
Disclosed funding & relationshipsPredominantly NHS commissioner income; own 2025/26 annual accounts also identify private-patient, research/development, charitable and commercial income. Specific page funding and expert payments not disclosed.
Use & limitsB, provisional — clinical care obligations and audited accounts favor accuracy; procedure-provider interests, local protocols and unknown page-specific conflicts remain.
Disclosed funding & relationshipsOriginal guideline declares NIH DK117824/DK092217 support to Pandolfino; other authors report no funding support. Pandolfino declares Ethicon, Diversatek, Crospon stock options and Medtronic speaking/consulting/FLIP licensing. Exact guideline-development financing not separately stated.
Use & limitsC, provisional — explicit recommendations and conflict disclosure; industry-linked author and older guidance prevent an independently cleared procedure/device ranking.
Source / disclosureNHS: achalasia
Disclosed funding & relationshipsUK public health service; statutory annual accounts provenance. Page-specific sponsor/expert payments not disclosed; individual-provider and research income can differ.
Use & limitsB, provisional — care accountability and clear triage guidance; simplified advice, December 2023; next review December 2026; not a trial-level financial audit.
View 7 more funding disclosures
Source / disclosureNHS: swallowing problems
Disclosed funding & relationshipsUK public health service; statutory annual accounts provenance. Page-specific sponsor/expert payments not disclosed; individual-provider and research income can differ.
Use & limitsB, provisional — care accountability and clear triage guidance; simplified advice, May 2023; stated review due May 2026 has passed; not a trial-level financial audit.
Disclosed funding & relationshipsPredominantly NHS commissioner income; own 2025/26 annual accounts also identify private-patient, research/development, charitable and commercial income. Specific page funding and expert payments not disclosed.
Use & limitsB, provisional — clinical care obligations and audited accounts favor accuracy; procedure-provider interests, local protocols and unknown page-specific conflicts remain.
Disclosed funding & relationshipsUniversity Hospitals Dorset’s own financial-report page identifies 2025/26 accounts, but full financial tables could not be retrieved in this review. National NHS accounts do not establish this trust’s actual revenue mix. Page-specific funding unknown.
Use & limitsC, provisional — identifiable clinical author and provider; September 2023 leaflet review due September 2026 has passed. Used for stable mechanism/nutrition context, not procedure ranking or numeric cancer risks.
Disclosed funding & relationshipsGOSH’s own reports identify 2025/26 accounts; full current report exceeded retrieval limits. Historical 2023/24 financial tables identify NHS and private-patient income; current detailed mix/page finance unresolved.
Use & limitsC, provisional — specialist paediatric provider; page reviewed June 2015 and overdue since 2016. Used only for childhood referral/follow-up context, not current procedural selection.
Disclosed funding & relationshipsUK public health service; statutory annual accounts provenance. Page-specific sponsor/expert payments not disclosed; individual-provider and research income can differ.
Use & limitsB, provisional — care accountability and clear triage guidance; simplified advice, April 2023; stated review due April 2026 has passed; not a trial-level financial audit.
Disclosed funding & relationshipsNIH Office of the Director; ODS public budget. No page-specific commercial sponsor named; cited trials were not all financially cleared.
Use & limitsB, provisional — referenced nutrient safety and public accountability; not proof of disease remission or individual suitability.
Disclosed funding & relationshipsNIH federal agency; NCCIH budget information. Page-level commercial sponsor not named; underlying review/trial funding not exhaustively traced.
Use & limitsB, provisional — public review and explicit uncertainty favor accuracy; an older synthesis does not certify any product or remove trial sponsorship.

This graphic reorganizes the article's disclosures; it is not a new financial audit or independence classification. Highlighted notes show different funding relationships where available. Review funding is separate from underlying trial funding. Disclosure is not proof of falsehood, and no declared conflict is not proof of complete independence.

The public publishers supply care context, not trial-level financial clearance. We checked the procedure provider’s own accounts rather than borrowing the national NHS funding label. The original ACG document discloses both NIH support and device-industry interests. It is retained for clinical context, with those conflicts visible; it is not used to certify a financially independent ranking. Older or incompletely retrieved hospital sources are explicitly limited below.

SourceFunding / backersCountry / jurisdictionIndependenceCredibility / incentives / gaps
NHS: achalasiaUK public health service; statutory annual accounts provenance. Page-specific sponsor/expert payments not disclosed; individual-provider and research income can differ.United Kingdom; NHS England national patient information.Tier 1 institutional education, provisional; complete page financing unknown.B, provisional — care accountability and clear triage guidance; simplified advice, December 2023; next review December 2026; not a trial-level financial audit.
NHS: swallowing problemsUK public health service; statutory annual accounts provenance. Page-specific sponsor/expert payments not disclosed; individual-provider and research income can differ.United Kingdom; NHS England national patient information.Tier 1 institutional education, provisional; complete page financing unknown.B, provisional — care accountability and clear triage guidance; simplified advice, May 2023; stated review due May 2026 has passed; not a trial-level financial audit.
Guy’s and St Thomas’: POEM overviewPredominantly NHS commissioner income; own 2025/26 annual accounts also identify private-patient, research/development, charitable and commercial income. Specific page funding and expert payments not disclosed.United Kingdom; Guy’s and St Thomas’ NHS Foundation Trust, London.Tier 2 institution, provisional; mixed public/private and commercial income.B, provisional — clinical care obligations and audited accounts favor accuracy; procedure-provider interests, local protocols and unknown page-specific conflicts remain.
Guy’s and St Thomas’: having POEM surgeryPredominantly NHS commissioner income; own 2025/26 annual accounts also identify private-patient, research/development, charitable and commercial income. Specific page funding and expert payments not disclosed.United Kingdom; Guy’s and St Thomas’ NHS Foundation Trust, London.Tier 2 institution, provisional; mixed public/private and commercial income.B, provisional — clinical care obligations and audited accounts favor accuracy; procedure-provider interests, local protocols and unknown page-specific conflicts remain.
ACG 2020 original achalasia guidelineOriginal guideline declares NIH DK117824/DK092217 support to Pandolfino; other authors report no funding support. Pandolfino declares Ethicon, Diversatek, Crospon stock options and Medtronic speaking/consulting/FLIP licensing. Exact guideline-development financing not separately stated.United States; lead author Vanderbilt, Nashville, Tennessee; collaborating US clinical institutions.Tier 3 for this review: declared device-industry financial interests.C, provisional — explicit recommendations and conflict disclosure; industry-linked author and older guidance prevent an independently cleared procedure/device ranking.
University Hospitals Dorset: achalasia leafletUniversity Hospitals Dorset’s own financial-report page identifies 2025/26 accounts, but full financial tables could not be retrieved in this review. National NHS accounts do not establish this trust’s actual revenue mix. Page-specific funding unknown.United Kingdom; University Hospitals Dorset NHS Foundation Trust, Bournemouth/Poole.Institutional independence unclassified; finance verification incomplete.C, provisional — identifiable clinical author and provider; September 2023 leaflet review due September 2026 has passed. Used for stable mechanism/nutrition context, not procedure ranking or numeric cancer risks.
Great Ormond Street Hospital: childhood achalasiaGOSH’s own reports identify 2025/26 accounts; full current report exceeded retrieval limits. Historical 2023/24 financial tables identify NHS and private-patient income; current detailed mix/page finance unresolved.United Kingdom; Great Ormond Street Hospital for Children NHS Foundation Trust, London.Tier 2 institution, provisional; historical mixed public/private income, current gaps.C, provisional — specialist paediatric provider; page reviewed June 2015 and overdue since 2016. Used only for childhood referral/follow-up context, not current procedural selection.
NHS: GTN medicine and supplement interactionsUK public health service; statutory annual accounts provenance. Page-specific sponsor/expert payments not disclosed; individual-provider and research income can differ.United Kingdom; NHS England national patient information.Tier 1 institutional education, provisional; complete page financing unknown.B, provisional — care accountability and clear triage guidance; simplified advice, April 2023; stated review due April 2026 has passed; not a trial-level financial audit.
NIH ODS: dietary supplement safetyNIH Office of the Director; ODS public budget. No page-specific commercial sponsor named; cited trials were not all financially cleared.United States; NIH ODS, Bethesda, Maryland; federal education.Tier 1 institutional context; source-trial financing varies.B, provisional — referenced nutrient safety and public accountability; not proof of disease remission or individual suitability.
NCCIH: using supplements wiselyNIH federal agency; NCCIH budget information. Page-level commercial sponsor not named; underlying review/trial funding not exhaustively traced.United States; NCCIH, Bethesda, Maryland; federal education.Tier 1 institution; underlying trials unclassified.B, provisional — public review and explicit uncertainty favor accuracy; an older synthesis does not certify any product or remove trial sponsorship.

Frequently asked questions

Is achalasia the same as acid reflux?

No. Reflux is backward movement of stomach contents; achalasia involves impaired oesophageal emptying. Symptoms can overlap, and reflux may occur after treatment. Diagnostic testing resolves the distinction.

Does surgery cure the underlying nerve problem?

Treatment reduces resistance to emptying and can provide sustained relief. It does not restore normal nerves, so recurrence and reflux still require follow-up.

Should everyone have the same procedure?

No. Discuss the manometry pattern, previous treatment, fitness, preferences and centre experience. This guide does not supply an independently cleared ranking.

Does achalasia mean I have cancer?

No. Long-term achalasia is associated with increased oesophageal cancer risk, while cancer can also mimic swallowing symptoms. NHS guidance emphasizes assessment; agree investigation and longer-term follow-up with the specialist rather than assuming either diagnosis.

Sources and funding notes

Sources were opened and checked on 4 October 2026. The ACG 2020 original is clinical context with declared industry ties; no commercially linked efficacy result supports an independent procedure ranking. Guy’s and St Thomas’ 2025/26 accounts were read directly. Dorset and GOSH current financial reports could not be fully retrieved, and their age-specific/page review limitations remain visible. No personal dosing, hospital diet timetable or supplement regimen is supplied.

  1. NHS: achalasia — Adult symptoms, complementary diagnostic tests and established treatment options.
  2. NHS: swallowing problems — Prompt assessment, aspiration warning signs and dietitian/swallowing-team involvement.
  3. Guy’s and St Thomas’: POEM overview — March 2025 patient information explaining POEM, alternatives and complications.
  4. Guy’s and St Thomas’: having POEM surgery — March 2025 local preparation, recovery and urgent postoperative warning signs; local schedules are not universal.
  5. ACG 2020 original achalasia guideline — Diagnostic subtypes and follow-up context; comparative efficacy trials and their finances not independently re-audited.
  6. University Hospitals Dorset: achalasia leaflet — Food retention, aspiration, diet and supportive practical context.
  7. Great Ormond Street Hospital: childhood achalasia — Children require specialist care and follow-up; old age-specific information explicitly limited.
  8. NHS: GTN medicine and supplement interactions — Example of nitrate interactions; clinician must check the exact prescribed medicine.
  9. NIH ODS: dietary supplement safety — Nutrient products, surgery interactions and limits of certification.
  10. NCCIH: using supplements wisely — Complementary product safety and disclosure; not achalasia efficacy evidence.

Educational information reviewed 4 October 2026. This guide supports an informed clinical discussion; it does not diagnose an individual or provide a personal treatment regimen.

Have a question — or want us to cover something?

Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.

We store your topic, message, optional email, and this page so we can manage and reply to the request. Do not include diagnoses, medications, or other sensitive medical information. See our Privacy Policy.